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Abstract 
Introduction: Recent studies showed that J waves were associated with higher incidence of 
ventricular tachyarrhythmia (VT/VF) in patients with idiopathic ventricular fibrillation (VF) and 
myocardial infarction. We sought to assess the association between J waves and VT/VF in 
patients with non-ischemic cardiomyopathy (NICM). 5 
Methods and Results: We retrospectively enrolled 109 patients (79 men; mean age, 60±15 years) 
with NICM who underwent implantable cardioverter defibrillator (ICD) implantation. The 
primary endpoint of this study was the occurrence of appropriate device therapy due to sustained 
VT/VF. The J wave was electrocardiographically defined as an elevation of the terminal portion 
of the QRS complex of >0.1 mV in at least 2 contiguous inferior or lateral leads. Among the 109 10 
patients, 37 (34%) experienced an episode of appropriate device therapy during a median 
follow-up period of 25.9 (IQR 11.5–54.3) months. Kaplan-Meier curves showed that the 
presence of J waves on the 12-lead ECG obtained before device implantation was associated 
with an increased occurrence of appropriate device therapy (P<0.001). Multivariate Cox 
proportional regression analysis revealed that the presence of J waves (HR 2.95; 95% CI 15 
1.31–6.64; P=0.009) was an independent predictor for the occurrence of appropriate device 
therapy. In the sub-group analysis of the patients with dilated or hypertrophic cardiomyopathy, J 
wave tended to increase the occurrence of appropriate device therapy (P=0.056 and P=0.092, 
respectively). 
Conclusions: The presence of J waves was an independent predictor for the occurrence of 20 
appropriate device therapy in patients with NICM who underwent ICD implantation. 
Key Words: Non-ischemic cardiomyopathy; J wave; ventricular tachyarrhythmia; implantable 
cardioverter defibrillator 
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Introduction 
The J wave has historically been regarded as an innocuous finding in healthy young people.1,2 
While considered benign, the potential role of the J wave in arrhythmogenicity has been 
suggested in experimental studies.3 Recent evidence has linked J waves to idiopathic ventricular 
fibrillation (VF) in patients with no structural heart disease.4-6 5 
Besides idiopathic VF, recent studies showed that the presence of a J wave was associated 
with higher incidence of ventricular tachyarrhythmia (VT/VF) in patients with Brugada 
syndrome,7-9 short QT syndrome,10 noncompaction cardiomyopathy,11 Takotsubo 
cardiomyopathy,12 and ischemic heart disease.13-18 However, it is still unknown whether there is 
an association between J waves and VT/VF occurrences in patients with non-ischemic 10 
cardiomyopathy (NICM). We hypothesized that concomitant J waves would carry an increased 
risk of a VT/VF occurrence in patients with NICM. Accordingly, the purpose of this study was to 
clarify this point. 
 
Methods 15 
Study Population 
Between October 2006 and April 2013, 162 consecutive patients with NICM who underwent 
implantable cardioverter defibrillator (ICD) implantation at the University of Tsukuba Hospital 
and Yokohama Rosai Hospital were retrospectively included in the present study. Among the 162 
patients, 45 patients had a QRS duration of more than 120 ms and 8 were lost to follow-up. After 20 
excluding these patients, the remaining 109 patients (79 men and 30 women; mean age, 60±15 
years) were finally included in this study (Figure 1). 
The primary endpoint of this study was the occurrence of appropriate device therapy 
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including shock and anti-tachycardia pacing (ATP) due to sustained VT/VF. Patients were 
classified on the basis of the occurrence of appropriate device therapy, and the clinical data were 
analyzed in both the event occurrence and no event occurrence study groups. Data collection 
covered the variables of age, sex, body mass index, comorbid disease, ejection fraction measured 
by echocardiography, medications before device implantation, and ECG findings. Hypertension, 5 
hypercholesterolemia, and diabetes mellitus were scored on the basis of the previous diagnosis 
and initiation of therapy. Ethical approval was obtained from the institutional review board of 
each participating hospital. Owing to the retrospective and observational nature of the present 
study, written informed consents were not necessary under Japanese law. 
 10 
ECG Analysis 
To blind the ECG interpreters from the patient clinical characteristics and groupings, all tracings 
were scanned and coded. We evaluated the last 12-lead ECG recorded before device implantation 
with sweep speed of 25 mm/sec, low cut filter of 0.05 Hz, and high cut filter of 150 Hz. The 
median duration from ECG recording to device implantation was 2 days (interquartile range 15 
[IQR] 1–6 days). The J wave was electrocardiographically defined as the presence of an 
end-QRS notch or slur on the downslope of a prominent R-wave and J peak (Jp) of >0.1 mV in at 
least 2 contiguous inferior (II, III, and aVF) or lateral (I, aVL, and V4 to V6) leads (Figure 2).19 
An end-QRS notch denoted a notch that occurs on the final 50% of the downslope of an R-wave 
occurring as the final segment of the QRS complex and an end-QRS slur was defined as an 20 
apparent slowing of the inscription of the waveform at the end of the QRS complex that merges 
with the ST-segment of the complex. Jp denoted the peak of a notch or onset of a slur and the 
amplitude of Jp was measured. The anterior precordial leads (V1 to V3) were excluded from the 
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analysis of the J wave. We used two predefined cutoff points (>0.1 mV and >0.2 mV) to assess 
the significance of the amplitude of Jp. Further, we analyzed ST-segment characteristics 
independently according to the criteria proposed by a consensus paper.19 J termination (Jt) 
denoted the end of a notch or slur. We classified ST-segment characteristics into 2 groups. J wave 
with an ascending ST-segment was defined as follows; the amplitude of the ST-segment 100ms 5 
after Jt was greater than the amplitude at Jt. On the other hand, the definition of J wave with a 
horizontal or descending ST-segment was that the amplitude of the ST-segment 100ms after Jt 
was less than or equal to the amplitude at Jt.19 We assessed the prevalence, localization, 
amplitude, morphology, and ST-segment of the J wave in both patient groups. Two trained 
investigators independently evaluated the baseline 12-lead ECGs for the presence of J waves 10 
with no knowledge of the other observer’s judgment or the clinical information. 
 
ICD Programming and Assessment of ICD Therapy 
The border between the ventricular tachycardia (VT) zone and the VF zone of an ICD was set 
around 280–320 ms according to the nominal settings of each maker. Typical cut off rate of VT 15 
zone was set around 360–400 ms with detection interval of 16 beats that depended on the cycle 
length of clinically documented VT. In VT zone, shock therapy followed some attempts of ATP. 
On the other hand, shock therapy is immediately performed in VF zone and ATP during charge 
period was applied if available. 
A well trained electrophysiologist reviewed all records of ICD therapy and adjudicated them 20 
as appropriate or inappropriate at an outpatient clinic or a ward. Inappropriate ICD therapies 
were not included in analyses of this study. 
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Statistical Analysis 
Continuous variables were expressed as means ± standard deviation or medians (interquartile 
range [IQR]). Comparisons between two groups were tested by an unpaired t-test or 
Mann-Whitney U-test according to the data distribution with or without normality. All 
categorical variables were presented as the number and percent in each group and were 5 
compared by a Fisher’s exact test. A comparison of the probability of the freedom from 
appropriate device therapy between the two groups was performed with Kaplan-Meier survival 
analysis. “Time 0” for the survival analyses was the date of device implantation. A univariate 
analysis of the patient characteristics was compared between the event occurrence group and no 
event occurrence group, and a multivariable Cox proportional regression analysis was performed 10 
to detect any independent significant predictors by adjusting for multiple variables (reported as 
the hazard ratio [HR] with a 95% confidence interval [CI]). Variables, including multivariable 
Cox proportional hazard models, were those that achieved statistical significance (P<0.05) or 
were close to significance (P<0.1) in the univariable analysis. A P value <0.05 was considered 
statistically significant. All analyses were performed with R (The R Foundation for Statistical 15 
Computing, Vienna, Austria, version 3.1.1). 
 
Results 
Demographic and Clinical Characteristics of the Patients with and without J Waves 
Underlying heart diseases included hypertrophic cardiomyopathy (HCM) in 43, dilated 20 
cardiomyopathy (DCM) in 35, arrhythmogenic right ventricular cardiomyopathy (ARVC) in 15, 
valvular heart disease in 5, cardiac sarcoidosis in 5, congenital heart disease in 2, myocarditis in 
2, and others in the remaining 2 patients. J waves were observed in 12 (11%) patients. There was 
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no significant difference in age, sex, comorbid disease, ejection fraction, medication, ECG 
findings, and the prevalence of primary prevention, syncope, and family history between the 
patients with and without J waves (Table 1). 
Out of 60 patients who received amiodarone, sustained VT/VF were documented in 35 
patients, non-sustained VT in 9, atrial fibrillation in 7, and both VT/VF and atrial fibrillation in 5 
the remaining 9. The ECG before taking amiodarone was available in 25 patients (J wave–3, no J 
wave–22). The presence and absence of J wave did not differ before and after taking amiodarone 
in all but 1 patient who acquired J wave after receiving amiodarone. 
 
Univariable and Multivariable Analyses for the Occurrence of Appropriate Device Therapy 10 
Among the 109 patients, 37 (34%) experienced an episode of appropriate device therapy during a 
median follow-up period of 25.9 (IQR 11.5–54.3) months. Kaplan-Meier curves showed that the 
presence of J waves on the 12-lead ECG obtained before device implantation was associated 
with an increased occurrence of appropriate device therapy (P<0.001 by log rank test, Figure 3). 
A multivariate Cox proportional regression analysis revealed that the presence of J waves (HR 15 
2.95; 95% CI 1.31–6.64; P=0.009) was an independent predictor for the occurrence of 
appropriate device therapy during the follow-up period (Table 2). ATP was attempted before 
cardioversion in 29 patients. The success rate of anti-tachycardia therapy did not differ 
significantly in the patients with and without J wave (86% vs. 92%; P=0.536). 
In the sub-group analysis of the patients with DCM or HCM, concomitant J wave tended to 20 
be associated with an increased risk of the occurrence of appropriate device therapy (P=0.056 
and P=0.092, respectively; Figure 4A, B). 
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Detailed Analyses of J Waves for Prediction of Event Occurrence 
J waves were present in 12 patients and were more prevalent in patients with appropriate device 
therapy (24% vs. 4%; P=0.003, Table 3). Among these 12 patients, the J-point elevation was in 
the inferior leads in 8 (67%) patients, in the lateral leads in the remaining 4 (33%) (Table 3). A J 
wave in the inferior leads was associated with increased event occurrence (16% vs. 3%; P=0.018, 5 
Table 3), whereas a J wave in the lateral leads or both leads was not (Table 3). 
A J wave amplitude of >0.2 mV was found in the inferior or lateral leads in 3 (25%) patients, 
and it did not differ significantly between the patients with and without event occurrence (Table 
3). 
The prevalence of a slurred J wave (11% vs. 0%; P=0.012) differed significantly between 10 
the patients with and without event occurrence, however that of a notched J wave did not (Table 
3). 
The prevalence of a J wave with horizontal/descending ST-segment was higher in the 
patients with event occurrence than in those without (19% vs. 4%; P=0.030). Conversely, the 
incidence of a J wave with upsloping ST-segment did not differ significantly between the two 15 
groups (Table 3). 
 
 
 
Discussion 20 
Main Findings 
To the best of our knowledge, this is the first time that the following findings have been reported: 
1) approximately 10% of the NICM patients had J waves on the ECG recorded before device 
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implantation; 2) only the presence of J waves was an independent predictor for the occurrence of 
appropriate device therapy in patients with NICM who underwent ICD implantation; 3) as 
features of a J wave pattern, J waves in the inferior leads, a slurred morphology, and J waves 
with horizontal/descending ST-segment were significantly associated with the occurrence of 
appropriate device therapy; and 4) in the sub-group analysis of the patients with DCM or HCM, 5 
concomitant J wave tended to be associated with an increased risk of the occurrence of 
appropriate device therapy. 
 
Proposed Mechanism of VT/VF in Patients with J Waves 
Transmural differences in the early phases (phases 1 and 2) of the cardiac action potential, which 10 
are created by a disproportionate amplification of the repolarizing current in the epicardial 
myocardium due to an increase in the outward potassium currents mediated by the Ito, IK-ATP, and 
IK-Ach channels, are considered to be responsible for the inscription of the ECG J wave.20 The 
trigger and substrate for the development of phase 2 reentry and VT/VF may eventually emerge 
from the transmural dispersion of the duration of the cardiac action potentials.20  15 
Although repolarization abnormalities were mainly recognized as a cause of J wave, we 
cannot exclude that J waves, at least some of them, are related to depolarization abnormalities. 
Patients with NICM have scar tissue in the myocardium that gives rise to activation delay due to 
lengthened conduction pathways and consequently could become a substrate for VT. We 
speculated that phase 2 reentry and scar tissue play an important role in the development of 20 
sustained VT/VF as the trigger and substrate, respectively, resulting in the higher prevalence of 
an occurrence of appropriate device therapy in the patients with J waves than in those without. 
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Previous Studies 
Although the link between J waves and VT/VF is well known in patients with idiopathic VF and 
ischemic cardiomyopathy, the association between J waves and VT/VF in patients with NICM 
remains unclear. Chan et al. investigated 59 patients with ARVC who underwent catheter 
ablation for VT and showed that the prevalence of induced VF was higher and the cycle length of 5 
VT was shorter during the procedure in the patients with J waves than in those without J waves.21 
Li et al. showed that the J wave was associated with an increased risk of sudden cardiac 
arrest in patients with HCM.22 The present study showed that a concomitant J wave predicted the 
increased occurrence of VT/VF not only in the patients with HCM but also in those with DCM. 
Previous studies have identified the characteristics of J waves in those who have suffered 10 
from VT/VF associated with idiopathic VF and myocardial infarction.14-17,23,24 In the present 
study, J waves in the inferior leads, a slurred morphology, and J waves with 
horizontal/descending ST-segment were associated with an increased risk of the occurrence of 
appropriate device therapy in the patients with NICM, which was similar to the findings of the 
previous studies. We consider that these J wave patterns could indicate a malignant form. 15 
 
Clinical Implications 
Our study showed that the presence of J waves increased the risk for the occurrence of 
appropriate device therapy in patients with NICM. In particular, increased attention should be 
paid to the patients with J waves in the inferior leads and J waves with horizontal/descending 20 
ST-segment. 
 
Study Limitations 
- 10 - 
 
First, our study is a hypothesis-generating trial, not a conclusive trial, based on a retrospective 
design and with a relatively small sample size. The small sample size limited the power of the 
study and was reflected in the broad confidence intervals, most notably in the adjusted statistical 
analyses. Second, we included various etiologies of NICM such as DCM, HCM, and ARVC. 
Third, the findings in this study were obtained during drug treatment in the large majority of the 5 
patients, including amiodarone with major impact on depolarization and repolarization criteria, 
and also the occurrence of fast VT. Fourth, our study population seemed to be high risk of 
appropriate device therapy during the median follow-up period of 26 months even though 
approximately half of the patients received ICD as a primary prevention. We speculated that high 
prevalence of sustained or non-sustained VT/VF in spite of taking amiodarone and relatively 10 
short detection interval of ICD therapy resulted in this findings. Fifth, we set high cut-off rate of 
VF zone (280–320ms) according to the nominal settings of each maker. This settings could be 
inappropriate because at cycle length above 250 ms the rhythm is usually not VF but VT and 
could be terminated by ATP. Therefore, further prospective studies with a larger sample size, 
long-term follow-up, and the participation of many hospitals and many countries may be needed 15 
to resolve these limitations and to confirm and enhance our results. 
 
Conclusion 
The presence of J waves was an independent predictor for the occurrence of appropriate device 
therapy in patients with NICM who underwent ICD implantation. 20 
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Figure Legends 
Figure 1. Study design. Patients excluded from the analysis are indicated by arrows directed to 
the right. ICD indicates implantable cardioverter defibrillator; and IQR, interquartile range. 
 
Figure 2. Representative cases of J waves. (A) Notched J waves (arrows) with 5 
horizontal/descending ST-segment in the inferior leads were recognized in a 73-year-old man 
with dilated cardiomyopathy. (B) Notched J waves (arrows) with horizontal/descending 
ST-segment in the lateral leads were observed in a 54-year-old man with hypertrophic 
cardiomyopathy. (C) A 62-year-old man with hypertrophic cardiomyopathy had slurred J waves 
(arrows) with horizontal/descending ST-segment in the inferior leads. 10 
 
Figure 3. Kaplan-Meier curves for the primary endpoint. There was a significant difference in 
the occurrence of appropriate device therapy between the patients with and without J waves. 
 
Figure 4. Kaplan-Meier curves in patients with dilated cardiomyopathy and hypertrophic 15 
cardiomyopathy. (A) Concomitant J waves tended to be associated with increased occurrence of 
appropriate device therapy in 35 patients with dilated cardiomyopathy. (B) Among 43 patients 
with hypertrophic cardiomyopathy, the occurrence of appropriate device therapy tended to be 
higher in the patients with J waves than in those without. 
20 
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Table 1.  Demographic and Clinical Characteristics of the Patients with and without J 
Waves 
 Total 
(n=109) 
With 
J waves 
Without 
J waves P value
Characteristics (n=12) (n=97) 
Age, years 60±15 63±14 60±15 0.529 
Male sex, n (%) 79 (72%) 9 (75%) 70 (72%) 1.0 
Comorbid disease     
Hypertension, n (%) 39 (36%) 4 (33%) 35 (36%) 1.0 
Hyperlipidemia, n (%) 25 (23%) 0 (0%) 25 (26%) 0.064 
Diabetes mellitus, n (%) 13 (12%) 3 (25%) 10 (10%) 0.154 
Atrial fibrillation, n (%) 25 (23%) 3 (25%) 22 (23%) 1.0 
Chronic kidney disease, n (%) 38 (35%) 3 (25%) 35 (36%) 0.536 
Primary prevention, n (%) 45 (41%) 5 (42%) 40 (41%) 1.0 
Non sustained VT, n (%) 30 (28%) 5 (42%) 25 (26%) 0.305 
Syncope, n (%) 32 (29%) 2 (17%) 30 (31%) 0.503 
Family history, n (%) 24 (22%) 3 (25%) 21 (22%) 0.724 
NYHA class 1 [1–2] 1 [1–2] 1 [1–2] 0.901 
Left ventricular ejection fraction, % 57±19 52±20 58±19 0.306 
Left ventricular ejection fraction 
<35%, n (%) 16 (15%) 3 (25%) 13 (13%) 0.379 
Medication     
β-blocker, n (%) 80 (73%) 8 (67%) 72 (74%) 0.730 
ACE-I/ARB, n (%) 69 (63%) 10 (83%) 59 (61%) 0.204 
Calcium channel blocker, n (%) 25 (23%) 4 (33%) 21 (22%) 0.465 
Amiodarone, n (%) 60 (55%) 8 (67%) 52 (54%) 0.542 
Digitalis, n (%) 2 (2%) 1 (8%) 1 (1%) 0.209 
ECG findings     
Heart rate, beats/minute 63±13 65±11 62±13 0.529 
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Values are reported as the mean ± standard deviation, median (interquartile range), or n (%). 
ACE-I indicates angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; 
LVH, left ventricular hypertrophy; VT, ventricular tachycardia; and NYHA, New York Heart 
Association. 
5 
QRS duration, ms 100±12 107±8 99±12 0.031 
QTc interval, ms 439±31 434±19 440±32 0.576 
LVH, n (%) 37 (34%) 3 (25%) 34 (35%) 0.748 
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Table 2. Univariable and Multivariable Cox Proportional Regression Analyses for the 
Occurrence of Ventricular Tachyarrhythmias or Sudden Death 
Variables 
Univariable Multivariable 
Hazard ratio 
(95% confidence interval) P value
Hazard ratio 
(95% confidence interval) P value 
Age 1.011 (0.988–1.034) 0.336   
Male sex 1.414 (0.719–2.780) 0.315   
Digitalis 4.437 (1.054–18.67) 0.042 1.528 (0.323–7.243) 0.593 
Ejection fraction 0.982 (0.965–0.999) 0.033 0.985 (0.968–1.003) 0.098 
Primary prevention 1.704 (0.886–3.279) 0.110   
NYHA class 1.188 (0.775–1.821) 0.429   
J wave 3.559 (1.675–7.560) 0.001 2.946 (1.307–6.642) 0.009 
NYHA indicates New York Heart Association. 
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Table 3.  Details of J waves in the Patients with and without Appropriate Device Therapy 
 
 Total 
(n=109) 
Event 
occurrence 
No event 
occurrence P value
 (n=37) (n=72) 
J wave 12 (11%) 9 (24%) 3 (4%) 0.003 
Distribution     
Inferior leads, n (%) 8 (7%) 6 (16%) 2 (3%) 0.018 
Lateral leads, n (%) 4 (4%) 3 (8%) 1 (1%) 0.112 
Both leads, n (%) 0 (0%) 0 (0%) 0 (0%) 1.0 
Amplitude of J point     
>0.2 mV, n (%) 3 (3%) 2 (5%) 1 (1%) 0.265 
Morphology     
Notching, n (%) 8 (7%) 5 (14%) 3 (4%) 0.118 
Slurring, n (%) 4 (3%) 4 (11%) 0 (0%) 0.012 
ST segment     
Upsloping ST segment, n (%) 2 (2%) 2 (5%) 0 (0%) 0.113 
Horizontal or descending ST 
segment, n (%) 10 (9%) 7 (19%) 3 (4%) 0.030 
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Figure and Figure captions 
 
Figure 1. Study design. Patients excluded from the analysis are indicated by arrows directed to 
the right. ICD indicates implantable cardioverter defibrillator; and IQR, interquartile range. 
5 
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Figure 2. Representative cases of J waves. (A) Notched J waves (arrows) with 
horizontal/descending ST-segment in the inferior leads were recognized in a 73-year-old man 
with dilated cardiomyopathy. (B) Notched J waves (arrows) with horizontal/descending 
ST-segment in the lateral leads were observed in a 54-year-old man with hypertrophic 5 
cardiomyopathy. (C) A 62-year-old man with hypertrophic cardiomyopathy had slurred J waves 
(arrows) with horizontal/descending ST-segment in the inferior leads. 
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Figure 3. Kaplan-Meier curves for the primary endpoint. There was a significant difference in 
the occurrence of appropriate device therapy between the patients with and without J waves. 
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Figure 4. Kaplan-Meier curves in patients with dilated cardiomyopathy and hypertrophic 
cardiomyopathy. (A) Concomitant J waves tended to be associated with increased occurrence of 
appropriate device therapy in 35 patients with dilated cardiomyopathy. (B) Among 43 patients 
with hypertrophic cardiomyopathy, the occurrence of appropriate device therapy tended to be 5 
higher in the patients with J waves than in those without. 
